Johnson & Johnson has requested emergency use authorization for its coronavirus vaccine, which if approved, would be the third vaccine available for distribution in the United States.
The company’s request to the U.S. Food and Drug Administration comes after data released last week showing its effectiveness against the virus at 66 percent. The company expected to have product available to ship immediately following authorization, according to a news release.
"These topline results with a single-shot COVID-19 vaccine candidate represent a promising moment," Johnson& Johnson Chief Scientific Officer Dr. Paul Stoffels said of the clinical trials last week.
So far, only Moderna and Pfizer-BioNTech’s two-shot vaccines have received approval from the FDA. They were given the green light in back-to-back weeks in December, and have been part of a rocky national rollout.
This is a developing story. Check back for updates.
Related
LISTEN NOW on the RADIO.COM App
Follow RADIO.COM
Facebook | Twitter | Instagram